Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Qiagen (DE:QIA)
:QIA
Holding DE:QIA?
Track your performance easily
QIA Stock Chart & Stats
Day’s Range― - ―
52-Week Range€36.59 - €45.02
Previous CloseN/A
Volume22.54K
Average Volume (3M)481.46K
Market Cap
€9.87B
Enterprise Value€10.65B
Total Cash (Recent Filing)$533.38M
Total Debt (Recent Filing)$1.07B
Price to Earnings (P/E)123.3
Beta0.48
Next Earnings
Feb 05, 2025EPS Estimate
0.59Last Dividend Ex-Date
Jan 30, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)0.36
Shares Outstanding221,847,000
10 Day Avg. Volume558,559
30 Day Avg. Volume481,464
Standard Deviation0.05
R-Squared0.00472
Alpha0.00657
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.33
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue10.49
Enterprise Value/Gross Profit8.63
Enterprise Value/Ebitda31.14
Forecast
1Y Price Target
€50.77Price Target Upside13.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
QIAGEN NV News
PremiumCompany Announcements
QIAGEN Finalizes $300 Million Synthetic Share Repurchase Plan
PremiumCompany Announcements
Qiagen N.V. Voting Rights Update: BlackRock’s Significant Stake Disclosed
PremiumCompany Announcements
QIAGEN Announces $300 Million Synthetic Share Repurchase Plan
PremiumCompany Announcements
Qiagen Announces BlackRock’s Significant Stake in CompanyPremiumCompany Announcements
Qiagen N.V. Announces Major Shareholder Voting Rights UpdateBulls Say, Bears Say
Bulls Say
Capital Allocation StrategyThe intent to return ~$300mn in shareholder capital is seen as a disciplined and shareholder-friendly capital allocation strategy by QIAGEN.
Operational Execution3Q was evidence of another solid quarter of commercial execution from QGEN, with organic growth, margins, EPS and FCF all ahead of plan.
Strong Financial PositionQGEN has a net debt-EBITDA of approximately 0.0x and projected free cash flow of more than $500M per year over the next three years, indicating a strong financial position.
Bears Say
CompetitionChannel checks suggest the QIAStat-Dx is seeing signs of competition in the US from labs consolidating their multiplex testing toward the market leader and shifting some volume to a newer/lower-cost competitor.
EarningsFactoring in lost interest income could result in a relative 1% cut to EPS as a result of the $300M deployment.
Product DemandQiagen's TB test (QFT) will see its third year of growth deceleration, signalling a normalization of testing demand.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.44% Insiders
21.00% Mutual Funds
0.38% Other Institutional Investors
64.05% Public Companies and Individual Investors
QIA FAQ
What was Qiagen’s price range in the past 12 months?
Qiagen lowest stock price was €36.59 and its highest was €45.02 in the past 12 months.
What is Qiagen’s market cap?
Qiagen’s market cap is €9.87B.
When is Qiagen’s upcoming earnings report date?
Qiagen’s upcoming earnings report date is Feb 05, 2025 which is in 14 days.
How were Qiagen’s earnings last quarter?
Qiagen released its earnings results on Nov 06, 2024. The company reported €0.556 earnings per share for the quarter, beating the consensus estimate of €0.53 by €0.026.
Is Qiagen overvalued?
According to Wall Street analysts Qiagen’s price is currently Undervalued.
Does Qiagen pay dividends?
Qiagen pays a Notavailable dividend of €1.24 which represents an annual dividend yield of N/A. See more information on Qiagen dividends here
What is Qiagen’s EPS estimate?
Qiagen’s EPS estimate is 0.59.
How many shares outstanding does Qiagen have?
Qiagen has 221,847,000 shares outstanding.
What happened to Qiagen’s price movement after its last earnings report?
Qiagen reported an EPS of €0.556 in its last earnings report, beating expectations of €0.53. Following the earnings report the stock price went up 2.83%.
Which hedge fund is a major shareholder of Qiagen?
Currently, no hedge funds are holding shares in DE:QIA
---
QIAGEN NV Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€50.77 (13.73% Upside)
€50.77 (13.73% Upside)
Blogger Sentiment
Bullish
DE:QIA Sentiment 70%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.82%
12-Months-Change
Fundamentals
Return on Equity
2.57%
Trailing 12-Months
Asset Growth
6.15%
Trailing 12-Months
Company Description
Qiagen
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
---
QIA Company Deck
---
QIA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with strong sales, earnings, and profitability improvements, despite cautious instrument spending and challenges in China. The company is on track with strategic growth initiatives and has increased its earnings outlook.Read More>---
QIA Stock 12 Month Forecast
Average Price Target
€50.77
▲(13.73% Upside)
Technical Analysis
Qiagen
―
Illumina
―
Thermo Fisher
―
Danaher
―
Bio-Rad Laboratories
―
Bio-Techne
―
Hologic
―
Best Analysts Covering QIA
1 Year
1 Year Success Rate
7/11 ratings generated profit
1 Year Average Return
+2.88%
reiterated a buy rating 7 months ago
Copying Patrick B Donnelly's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +2.88% per trade.
---